Skip to content
Home/Companies/Biotech/Boundless Bio
Boundless Bio

Boundless Bio

Biotech·US·Exited 2024·Held 1yr
Entry
2023
Hold
1yr
Exit
2024

Who owns Boundless Bio?

Boundless Bio was owned by Leaps by Bayer through Leaps by Bayer (2015 vintage) from 2023 to 2024, exited via IPO.

Hand-verified · updated 2026-07-03

Leaps by Bayer
Investor
Leaps by Bayer
Leaps by Bayer · 2015 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Websiteboundlessbio.com
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2024

More from Leaps by Bayer

Other portfolio companies in the same fund.

Celea Therapeutics
Celea Therapeutics
Active
BiotechUS· 2026
Leaf Agriculture
Active
ClimateTechUS· 2026
Sabanto
Active
AgTechUS· 2026
SonoThera
SonoThera
Active
BiotechUS· 2026
Souffle Therapeutics
Active
BiotechUS· 2025
WellTheory
WellTheory
Active
HealthTechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Boundless Bio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Boundless Bio?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Boundless Bio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue